Global Rifabutin market is experiencing a steady upward trajectory driven by rising demand for targeted antimycobacterial therapies and increased awareness of complex opportunistic infections. Valued at USD 125 million in 2024, the market is projected to reach approximately USD 180 million by 2032, registering a CAGR of 4.2%. As advancements in infectious disease management and public... https://www.24lifesciences.com/rifabutin-market-10351